- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04331002
Success of Long-acting Anti-inflammatories After Anterior Cruciate Ligament and Meniscal Injury (SLAM)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Anterior cruciate ligament (ACL) injury initiates a biochemical cascade that leads to cartilage degradation and the development of posttraumatic osteoarthritis (PTOA). ACL and acute traumatic meniscus tears have been linked to the development and progression of PTOA. As such, there is an unmet need to identify treatments that may alter the progression of PTOA following ACL meniscus injury. The overarching hypothesis of this project is that intraarticular administration of long-acting anti-inflammatory agents will alter the progression of PTOA following ACL reconstruction.
The current standard of care for patients with combined ACL and meniscus injuries consists of surgical treatment often with a short course of postoperative physical therapy. However, the current mechanically-based standard of care does not address the persistent inflammatory process that promotes cartilage degradation and PTOA progression. The pro-inflammatory stimulation of meniscus cells increases matrix metalloproteinase (MMP) and cytokine activity, and the combination of pro-inflammatory cytokines and compressive loading like what may be seen during sporting and high demand activities further results in degradative enzyme activity and increased production of pro-inflammatory mediators. In this way, the meniscus plays an active role in promoting the cycle of articular cartilage degradation and PTOA progression after ACL reconstruction.
Reducing MMP and cytokine activity after ACL and meniscus injury may alter the progression of PTOA for this at-risk patient population. After ACL injury and reconstruction demonstrate triamcinolone acetonide effectively reduces cartilage degradation, the inflammatory cascade and corresponding cartilage degradation are reinitiated after surgery, hyaluronate treatment 1 week after surgery unsuccessfully mitigates the inflammatory and catabolic processes, and pain and persistent postsurgical cytokine activity at 4 weeks were predictive of inferior knee biomechanics 6 months after surgery. In addition, long-acting agents may provide a greater treatment effect as temporal regulation of cytokine activity may more successfully alter the pro-inflammatory environment than shorter-duration treatments. These results identify that long-acting anti-inflammatory treatment is needed to alter the path of PTOA following meniscus injury and administration 8 weeks after surgery may offer the optimal timing of treatment.
The model whereby femoral shape change and cytokine activity are mediated by a long-acting anti-inflammatory agent (extended-release triamcinolone acetonide) will be tested. Femoral shape changes have been demonstrated after ACL injury and reconstruction, with shape changes in the first 6 months after surgery correlating with subsequent MRI evidence of cartilage degradation and inferior patient-reported outcomes 3 years postoperatively. A Phase 2a, double-blind, placebo-controlled, randomized controlled trial will be performed. The trial will determine if a long-acting anti-inflammatory agent (extended-release triamcinolone acetonide) improves patient-reported outcomes and/or lessens progressive bone shape changes or cartilage breakdown when compared to placebo (saline). Saline was chosen as the placebo as saline has few potential risks and rare adverse events and is the most commonly used placebo treatment option used in knee osteoarthritis research.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Kentucky
-
Lexington, Kentucky, United States, 40504
- UK Healthcare at Turfland
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written consent to participate in the study
- Male or female greater than or equal to 18 years of age and less than 40 years of age
- Has been consented to undergo arthroscopic ACL reconstruction with partial meniscectomy or meniscal repair
- Ambulatory and in good general health
- Willing and able to comply with the study procedures and visit schedules and able to follow verbal and written instructions.
- Willing to abstain from use of protocol-restricted medications during the study
- Females and males who have reproductive potential: Must use highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation (10 weeks; 4 to 14 weeks after surgery)
- Demonstrate persistent inflammation defined as synovial fluid IL-1a concentration greater than or equal to 5 pg/mL at the time of surgery
Exclusion Criteria:
- Known allergic reactions to components of the extended-release triamcinolone acetonide (Zilretta®)
- Reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease
- History of infection in either knee joint
- Clinical signs and symptoms of active knee infection or crystal disease in either knee within 1 month of Screening
- Other surgery or arthroscopy of either knee within 6 months of Screening
- Intraarticular treatment of any joint with any of the following agents within six (6) months of Screening: any corticosteroid preparation or any biologic agent (e.g., platelet rich plasma (PRP) injection, stem cells, prolotherapy, amniotic fluid injection; investigational or marketed).
- Intraarticular treatment in either knee with hyaluronic acid (investigational or marketed) within 6 months of Screening
- Parenteral or oral corticosteroids (investigational or marketed) within 3 months of Screening
- Inhaled, intranasal or topical corticosteroids (investigational or marketed) within 2 weeks of Screening
- Females who are pregnant or nursing or plan to become pregnant during the study; men whose female partner plans to conceive during the study
- Radiographic osteoarthritic changes defined as Kellgren-Lawrence grade 2 or greater (as determined by PI from patient's preoperative X-rays)
- Inability to read and understand English
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental
The experimental group will receive a single 32 mg Zilretta injection approximately 8 weeks after meniscus surgery.
|
ZILRETTA is an injectable suspension that delivers 32 mg of triamcinolone acetonide.
It is supplied as a single-dose kit containing one vial of ZILRETTA microsphere powder, one vial of 5 mL diluent, and one sterile vial adapter.
Other Names:
|
Placebo Comparator: Placebo
The placebo group will receive a single 5 mL injection of normal saline approximately 8 weeks after meniscus surgery.
|
5 mL normal saline
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Bone Shape (Baseline to 4 Months)
Time Frame: Baseline, 4 months
|
Using manual segmentation, the volume of the medial femoral condyle will be quantified from 3-Tesla magnetic resonance imaging (MRI) scans performed before and 4 months after the study injection.
Medial condyle volume will be expressed as cm3.
|
Baseline, 4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in IKDC (Baseline to 4 Months)
Time Frame: Baseline, 4 months, 1 year, 2 years
|
The International Knee Documentation Committee (IKDC) scores range from 0-100 with greater scores being indicative of greater self-reported function and reduced pain.
|
Baseline, 4 months, 1 year, 2 years
|
Change in IKDC (Baseline to 1 Year)
Time Frame: Baseline, 4 months, 1 year, 2 years
|
The International Knee Documentation Committee (IKDC) scores range from 0-100 with greater scores being indicative of greater self-reported function and reduced pain.
|
Baseline, 4 months, 1 year, 2 years
|
Change in IKDC (Baseline to 2 Years)
Time Frame: Baseline, 4 months, 1 year, 2 years
|
The International Knee Documentation Committee (IKDC) scores range from 0-100 with greater scores being indicative of greater self-reported function and reduced pain.
|
Baseline, 4 months, 1 year, 2 years
|
Change in KOOS Global (Baseline to 4 Months)
Time Frame: Baseline, 4 months, 1 year, 2 years
|
The Knee injury and Osteoarthritis Outcome Score (KOOS) Global scores range from 0-100 with greater scores being indicative of greater self-reported knee function and reduced pain and symptoms.
|
Baseline, 4 months, 1 year, 2 years
|
Change in KOOSglobal (Baseline to 1 Year)
Time Frame: Baseline, 4 months, 1 year, 2 years
|
The Knee injury and Osteoarthritis Outcome Score (KOOS) Global scores range from 0-100 with greater scores being indicative of greater self-reported knee function and reduced pain and symptoms.
|
Baseline, 4 months, 1 year, 2 years
|
Change in KOOSglobal (Baseline to 2 Years)
Time Frame: Baseline, 4 months, 1 year, 2 years
|
The Knee injury and Osteoarthritis Outcome Score (KOOS) Global scores range from 0-100 with greater scores being indicative of greater self-reported knee function and reduced pain and symptoms.
|
Baseline, 4 months, 1 year, 2 years
|
Change in ICOAP (Baseline to 4 Months)
Time Frame: Baseline, 4 months, 1 year, 2 years
|
The Intermittent and Constant Osteoarthritis Pain (ICOAP) Score is a valid and reliable tool to assess osteoarthritis-related pain.
Scores range from 0 to 100, with greater scores indicating worse pain.
|
Baseline, 4 months, 1 year, 2 years
|
Change in ICOAP (Baseline to 1 Year)
Time Frame: Baseline, 4 months, 1 year, 2 years
|
The Intermittent and Constant Osteoarthritis Pain (ICOAP) Score is a valid and reliable tool to assess osteoarthritis-related pain.
Scores range from 0 to 100, with greater scores indicating worse pain.
|
Baseline, 4 months, 1 year, 2 years
|
Change in ICOAP (Baseline to 2 Years)
Time Frame: Baseline, 4 months, 1 year, 2 years
|
The Intermittent and Constant Osteoarthritis Pain (ICOAP) Score is a valid and reliable tool to assess osteoarthritis-related pain.
Scores range from 0 to 100, with greater scores indicating worse pain.
|
Baseline, 4 months, 1 year, 2 years
|
Change in CTXII (Baseline to 4 Months)
Time Frame: Baseline, 4 months
|
C-terminal cross-linked telopeptides (CTX); CTXII levels measured by ELISA.
CTXII is a biomarker of type II collagen breakdown
|
Baseline, 4 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Austin Stone, MD, PhD, University of Kentucky
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Leg Injuries
- Knee Injuries
- Wounds and Injuries
- Anterior Cruciate Ligament Injuries
- Tibial Meniscus Injuries
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Immunosuppressive Agents
- Immunologic Factors
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Triamcinolone
- Triamcinolone Acetonide
- Triamcinolone hexacetonide
- Triamcinolone diacetate
Other Study ID Numbers
- 53136
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
With the participant's approval and as approved by local Institutional Review Boards (IRBs), de-identified biological samples will be stored at the University of Kentucky Orthopedic Biomarker Repository. These samples could be used to research the causes of osteoarthritis after meniscus injury, its complications and other conditions for which individuals with meniscus injuries are at increased risk, and to improve treatment.
Before sharing biomarker samples, we will ensure that the participant has given previous consent to the sharing of the information or samples. When we confirm that the previously provided consent is still in effect we will remove identifiers such as (e.g., name, medical record number, or date of birth). We will use a secure electronic log to track information shared without releasing the individual participant's identity.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anterior Cruciate Ligament Tear
-
Taipei Hospital, Ministry of Health and WelfareRecruitingAnterior Cruciate Ligament Tear | Posterior Cruciate Ligament TearTaiwan
-
Miach OrthopaedicsActive, not recruitingAnterior Cruciate Ligament Tear | Anterior Cruciate Ligament InjuryUnited States
-
University of Colorado, DenverChildren's Hospital ColoradoRecruitingAnterior Cruciate Ligament Injuries | Anterior Cruciate Ligament Rupture | Anterior Cruciate Ligament TearUnited States
-
Karolinska InstitutetRecruitingAnterior Cruciate Ligament Injuries | Anterior Cruciate Ligament Rupture | Anterior Cruciate Ligament TearSweden
-
Bahçeşehir UniversityIstanbul University - Cerrahpasa (IUC)CompletedAnterior Cruciate Ligament Injuries | Anterior Cruciate Ligament Rupture | Anterior Cruciate Ligament TearTurkey
-
Artromedical Konrad Malinowski ClinicRecruitingAnalysis of Radiological Features of Lateral Femoral Impaction Fracture / Lateral Femoral Notch SignAnterior Cruciate Ligament Injuries | Anterior Cruciate Ligament Rupture | Anterior Cruciate Ligament TearPoland
-
Artromedical Konrad Malinowski ClinicRecruitingAnterior Cruciate Ligament Injuries | Anterior Cruciate Ligament Rupture | Anterior Cruciate Ligament TearPoland
-
Liverpool University Hospitals NHS Foundation TrustRecruitingAnterior Cruciate Ligament Injuries | Anterior Cruciate Ligament Rupture | Anterior Cruciate Ligament TearUnited Kingdom
-
University of BathVersus ArthritisRecruitingPost-traumatic Osteoarthritis | Anterior Cruciate Ligament Injuries | Anterior Cruciate Ligament Rupture | Anterior Cruciate Ligament Tear | Anterior Cruciate Ligament ReconstructionUnited Kingdom
-
eMKa MED Medical CenterWroclaw Medical UniversityRecruitingAnterior Cruciate Ligament Injuries | Anterior Cruciate Ligament Rupture | Anterior Cruciate Ligament Tear | Knee Injuries | Knee Ligament InjuryPoland
Clinical Trials on Zilretta
-
Pacira Pharmaceuticals, IncMedpace, Inc.TerminatedAdhesive Capsulitis | Osteoarthritis of the ShoulderUnited States
-
Pacira Pharmaceuticals, IncCompletedOsteoarthritis, KneeUnited States, United Kingdom
-
Pacira Pharmaceuticals, IncCompletedOsteoarthritis of the KneeUnited States, Canada
-
Ohio State UniversityTerminatedOsteoarthritis, KneeUnited States
-
University of Kansas Medical CenterCompletedKnee OsteoarthritisUnited States
-
The Cleveland ClinicArthritis FoundationEnrolling by invitationOsteoarthritis, Knee | Meniscus; Degeneration | Synovitis | Meniscus TearUnited States
-
University of VirginiaRecruitingAdhesive Capsulitis of Shoulder | Adhesive Capsulitis | Frozen ShoulderUnited States
-
Pacira Pharmaceuticals, IncRecruiting
-
University of North Carolina, Chapel HillFlexion Therapeutics, Inc.Completed
-
Sorrento Therapeutics, Inc.Active, not recruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain ChronicUnited States